Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Physiomics and Merck team up to progress Virtual Tumour technology

This is a significant milestone for the company as it will generate long-term revenues with management expecting income of £500,000 to be realised in the first 12 months.
Picture of the word Merck
The agreement represents a significant external validation of its Virtual Tumour technology

In a double dose of good news, Physiomics plc (LON:PYC) announced that the human Virtual Tumour ("VT") project being conducted with leading science and technology company, Merck, first announced in March 2015, has been successfully completed.

Further, Physiomics said that it had today entered into a master services agreement with Merck.

This is a significant milestone for the company as it will generate long-term revenues with management expecting income of £500,000 to be realised in the first 12 months.

The company’s shares surged 270% on the back of this news to hit an intraday high of 365p, matching its 12 month high.

Interestingly, it is just over five years since Physiomic's shares spiked as news of a tie-up with a top-five pharma company was announced.

READ: Physiomics wins contract from 'top five pharma company', shares soar

Relationship with Merck strengthened

Not only is this development financially beneficial for Physiomics, it strengthens the group's relationship with a large multinational player and is an endorsement of the value that has been added over five years of working with Merck.

During this period, Physiomics has completed twelve projects involving pre-clinical, and more recently clinical predictions, with other projects in progress.

Management is of the view that the agreement represents a significant external validation of its Virtual Tumour technology, acknowledging its ability to successfully model the combination affects of treatments having different mechanisms of action at the cellular level, and its ability to scale this up to allow meaningful predictions of overall tumour growth.

Putting these developments into perspective, Dr Jim Millen, CEO Physiomics said: "We are very proud to be working with Merck, one of the world's top pharmaceutical companies, in an area as important and rapidly growing as oncology, and we believe this agreement marks the beginning of a new, longer-term relationship with this important client."

View full PYC profile View Profile

Physiomics Plc Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
1528305384_Untitled-design-(3).jpg
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use